Camelia pharmacy chain has been acquired by Medigate Management UAB
CGP Management UAB has sold the Camelia pharmacy chain (UAB Nemuno vaistinė and subsidiaries) to Medigate Management UAB.
UAB Nemuno vaistinė, operating under the brand name Camelia, is the leading pharmacy chain in Lithuania. The group carries out retail and wholesale trade in pharmaceuticals, food supplements, medical devices and cosmetics. Camelia’s pharmacy chain includes a countrywide network of approximately 300 own and 30 franchise outlets and manages one of the leading online pharmacies in Lithuania. Besides pharmacy retail and wholesale, the group is also involved in the development of pharmaceutical and nutraceutical products under its own brand names (private label).
Medigate Management UAB is a private investment holding company owned by Mr. Petras Bartkus (a minority shareholder in Camelia before the transaction). Medigate Management owns UAB Medigate, a developer and wholesaler of food supplements, medical devices and cosmetics in Lithuania.
CGP Management UAB is a private holding company owned by the founder of the Camelia pharmacy chain.
Oaklins’ team in Lithuania acted as the sole financial advisor to CGP Management on the sale of the Camelia pharmacy chain to Medigate Management.
Talk to the deal team
Related deals
Armira has signed an agreement to acquire a majority stake in Viabus
Armira, a Germany-based investment firm, has signed an agreement to acquire a majority stake in Viabus, a leading Dutch tour operator focused on senior and young senior travelers.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more